Raymond James Financial Services Advisors’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-365	Closed	-$6K	–	2974
2019 Q3	$6K	Hold	365	–	–	﹤0.01%	2789
2019 Q2	$8K	Hold	365	–	–	﹤0.01%	2824
2019 Q1	$25K	Hold	365	–	–	﹤0.01%	2743
2018 Q4	$19K	Hold	365	–	–	﹤0.01%	2518
2018 Q3	$25K	Sell	365 -25	-6%	-$2.27K	﹤0.01%	2750
2018 Q2	$46K	Buy	+390	New	+$39.1K	﹤0.01%	2674

Other funds holding SRRA

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return

Raymond James Financial Services Advisors's SRRA Position: Q4 2019 in Review

Raymond James Financial Services Advisors sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q4 2019, closing a stake of 365 shares — an estimated $6K sold.

Raymond James Financial Services Advisors first reported a position in SRRA in Q2 2018 and held it in 6 quarters. The position peaked at $46K in Q2 2018. 29 funds tracked by Wall St. Rank hold SRRA as of Q4 2019.

Raymond James Financial Services Advisors reported no remaining Sierra Oncology, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Raymond James Financial Services Advisors sold 365 Sierra Oncology, Inc. Common Stock shares in Q4 2019, an estimated $6K.
Raymond James Financial Services Advisors first reported a position in Sierra Oncology, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
Raymond James Financial Services Advisors's Sierra Oncology, Inc. Common Stock position peaked at $46K in Q2 2018.
29 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q4 2019.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.